Synthimed Labs
Synthimed Labs is a B2B Indian pharmaceutical company manufacturing Active Pharmaceutical Ingredients, providing CRAMS services, and supplying impurity reference standards to global pharmaceutical formulators, with reported global leadership in the macrolide antibiotic segment.
- Company typePrivate
- Founded2024
- HeadquartersChandigarh, India
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Synthimed Labs does
Synthimed Labs Private Limited is an India-based B2B pharmaceutical company that manufactures Active Pharmaceutical Ingredients (APIs), provides Contract Research and Manufacturing Services (CRAMS), and supplies impurity reference standards for the global pharmaceutical industry. The company was established in March 2024 by India Resurgence Fund (IndiaRF), a joint venture between Piramal Group and Bain Capital, as a special purpose vehicle to acquire and operate the carved-out generic API and CRAMS business of Ind-Swift Laboratories for ₹1,650 crore. Its API portfolio spans ten or more therapeutic areas including cardiovascular, oncology, anti-infectives, anti-diabetic, anti-histamine, anti-psychotic, anti-migraine, Parkinson's disease, ADHD, and alcohol abstinence treatments, with the company claiming global leadership in the macrolide antibiotic segment.
Synthimed operates integrated manufacturing facilities at Derabassi and Samba in Punjab, a dedicated R&D centre in Mohali for CRAMS and impurities work, corporate headquarters in Chandigarh, and regional marketing offices in New Delhi (India/SE Asia) and Dover, Delaware (US/Canada), with coverage extending to Europe and the rest of the world. It holds one of the broadest stacks of multi-jurisdictional regulatory approvals in the Indian API sector, including USFDA, EU GMP, WHO GMP, EDQM, ANVISA, KFDA, PMDA, Cofepris, JAZMP, and Australian Government certifications, supported by a clean zero-observation ANVISA Brazil cGMP inspection in June 2024. The company employs over 3,000 people and reports FY25 revenue of ₹1,452 crore with EBITDA of ₹469 crore, implying a ~32% margin.
The business model is B2B and primarily transaction-based: bulk API sales to pharmaceutical formulators, custom synthesis and process development work under CRAMS contracts, and catalogue sales of 263+ impurity reference standards under BP, EP, USP and other pharmacopoeial standards. Go-to-market is sales-led with regional sales contacts, supported by participation in global pharmaceutical trade shows including CPHI Milan, CPHI India, CPHI Middle East, and CPHI China. Pricing is quote-based and not publicly disclosed. IndiaRF is currently executing a minority stake sale at an approximately $1 billion valuation with Rothschild & Co advising and General Atlantic, KKR, and CVC Capital Partners among the prospective investors, in parallel with IPO preparation.
Synthimed Labs firmographics
Firmographics- Name
- Synthimed Labs
- Legal name
- Synthimed Labs Private Limited
- Website
- https://synthimed.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Synthimed Labs is a B2B Indian pharmaceutical company manufacturing Active Pharmaceutical Ingredients, providing CRAMS services, and supplying impurity reference standards to global pharmaceutical formulators, with reported global leadership in the macrolide antibiotic segment.
- Ownership category
- akta.pro rank
Synthimed Labs industry classification
Industry- Product category
- Active Pharmaceutical Ingredients (API) Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)
- akta.pro secondary industries
- Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Synthimed Labs is headquartered
LocationHeadquarters
- HQ city
- Chandigarh
- HQ country
- India
- HQ region
- Asia
Offices6 records
Markets served
Synthimed Labs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- API Sales: Sale of Active Pharmaceutical Ingredients to pharmaceutical formulators and distributors worldwide. Revenue generated from bulk manufacturing and supply of APIs across therapeutic segments.
- Impurity Reference Standards: Supply of pharmaceutical impurity reference standards and reference standards for APIs under BP, EP, USP and other pharmacopoeias. Products shipped with Certificate of Analysis and MSDS documentation.
- CRAMS Services: Contract Research and Manufacturing Services providing custom synthesis and process development for pharmaceutical compounds on behalf of clients.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Synthimed Labs product offering
Product offeringCore offering
Synthimed Labs manufactures and supplies high-quality Active Pharmaceutical Ingredients (APIs) across therapeutic areas including oncology, cardiovascular, anti-infectives, anti-diabetic, anti-histamine, anti-psychotics, anti-migraine, Parkinson's disease, ADHD, and alcohol abstinence treatments, with global dominance in the macrolide antibiotic segment. The company also provides Contract Research and Manufacturing Services (CRAMS) for custom synthesis and process development, and supplies 263+ impurity reference standards for APIs under BP, EP, USP and other pharmacopoeias with full Certificate of Analysis and MSDS documentation.
Product overview
Synthimed Labs operates as a pharmaceutical company with a multi-product portfolio comprising Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), and Impurities/Reference Standards. The company was established in March 2024 as a special purpose vehicle to house the carved-out generic API and CRAMS business acquired from Ind-Swift Laboratories for ₹1,650 crore. Their API portfolio covers therapeutic areas including cardiovascular health, anti-histamine, anti-diabetic, anti-psychotic, anti-migraine, Parkinson's disease, antineoplastic, ADHD symptoms, alcohol abstinence, and bone resorption inhibitor treatments, with global dominance in the macrolide antibiotic segment. The CRAMS division provides contract research and manufacturing services, while their impurity portfolio offers reference standards for numerous APIs under BP, EP, USP and other standards.
Differentiator
Problem solved
Functional benefit
Products and services
- Active Pharmaceutical Ingredients (APIs) Bulk Active Pharmaceutical Ingredients supplied to global pharmaceutical formulators across therapeutic areas including oncology, cardiovascular, anti-infectives, anti-diabetic, anti-histamine, anti-psychotics, anti-migraine, Parkinson's disease, ADHD, and alcohol abstinence treatments, with global leadership in the macrolide antibiotic segment.
- CRAMS (Contract Research and Manufacturing Services) Contract research, custom synthesis, and process development services for complex pharmaceutical intermediates and APIs, delivered to pharmaceutical companies lacking in-house capability or capacity for specialized molecules.
- Impurities and Reference Standards Portfolio of 263+ pharmaceutical impurity reference standards for APIs under BP, EP, USP and other pharmacopoeias, stocked for quick and reliable supply with full regulatory documentation including Certificate of Analysis and MSDS.
Quantifiable outcome
- cGMP inspection completed without any observations by ANVISA Brazil in June 2024
- +3 more outcomes
Companies that use Synthimed Labs
Customer profileSegments3 records
Ideal customer profiles3 records
Synthimed Labs technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Synthimed Labs partnerships and signals
Strategic signalScale indicators8 records
Recent moves8 records
Expansion highlights6 records
Synthimed Labs competitors and assessment
Company assessmentDirect peers
- Aurobindo Pharma: Large Indian generic API and finished-dose manufacturer with USFDA/EU GMP-certified facilities and a similarly broad therapeutic-area API portfolio (anti-infectives, cardiovascular, CNS). Direct competitor in regulated generic APIs targeting the same global formulators.
- Divi's Laboratories: India-based manufacturer of active pharmaceutical ingredients and intermediates with a major CRAMS/custom synthesis business. Highly comparable to Synthimed's API + CRAMS + complex-chemistry mix, and similarly supplies global innovator and generic customers.
- Laurus Labs: Indian API manufacturer with a strong anti-infective/anti-retroviral franchise and growing CDMO/CRAMS business. Directly competes with Synthimed in small-molecule APIs and contract manufacturing for global pharma customers.
- Suven Pharmaceuticals: India-based pure-play CRAMS/CDMO company providing custom synthesis and contract manufacturing for global pharma. Comparable to Synthimed's CRAMS vertical in service offering and customer base.
- Jubilant Pharmova: Indian pharmaceuticals company combining generic APIs, CRAMS/CDMO, and radiopharma. Directly comparable to Synthimed's small-molecule API and CRAMS businesses, particularly in complex chemistries.
- Sai Life Sciences: India-headquartered CRAMS/CDMO offering API development and manufacturing for global innovator pharma. Closely aligned with Synthimed's CRAMS vertical in customer profile and delivery model.
- MSN Laboratories: Indian API and finished-formulation manufacturer with USFDA-approved facilities serving regulated markets. Competes directly with Synthimed across cardiovascular, anti-diabetic, and CNS API categories.
- Ipca Laboratories: Indian generic API and formulations manufacturer with USFDA/EU GMP certifications and a similarly diverse therapeutic footprint. Direct competitor in regulated small-molecule APIs.
- Granules India: Indian manufacturer of APIs and finished dosages with a focus on cost-efficient high-volume generics. Overlaps with Synthimed in API supply to global generic formulators.
Broad incumbents
- Piramal Pharma Solutions: Global CDMO offering integrated API, drug product, and biologics services. Indirectly connected to Synthimed via the IndiaRF/Piramal relationship, and competes for the same CRAMS opportunities with broader scope (includes biologics).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Synthimed Labs social profiles
Digital presenceSynthimed Labs compliance and trust
Trust signalCompliance12 records
Synthimed Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Synthimed Labs leadership team
Management profileNumber of profiles
Profiles3 records
Synthimed Labs funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Synthimed Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Synthimed Labs
What does Synthimed Labs do?
Synthimed Labs manufactures and supplies high-quality Active Pharmaceutical Ingredients (APIs) across therapeutic areas including oncology, cardiovascular, anti-infectives, anti-diabetic, anti-histamine, anti-psychotics, anti-migraine, Parkinson's disease, ADHD, and alcohol abstinence treatments, with global dominance in the macrolide antibiotic segment. The company also provides Contract Research and Manufacturing Services (CRAMS) for custom synthesis and process development, and supplies 263+ impurity reference standards for APIs under BP, EP, USP and other pharmacopoeias with full Certificate of Analysis and MSDS documentation.
Is Synthimed Labs a public or private company?
Synthimed Labs is a private company. It is classified as private equity controlled and is currently operating.
When was Synthimed Labs founded?
Synthimed Labs was founded in 2024. It employs 501 to 1,000 people.
Where is Synthimed Labs based?
Synthimed Labs is headquartered in Chandigarh, India, in the Asia region.
How does Synthimed Labs make money?
Three revenue lines are on record. API Sales are the primary driver. The others are impurity Reference Standards and CRAMS Services.
Who are Synthimed Labs's main competitors?
Direct peers on record are Aurobindo Pharma, Divi's Laboratories, Laurus Labs, Suven Pharmaceuticals, Jubilant Pharmova, Sai Life Sciences, MSN Laboratories, Ipca Laboratories and Granules India. Piramal Pharma Solutions is listed as a broad incumbent.
Does Synthimed Labs have an API?
No public API is recorded for Synthimed Labs.
What industry is Synthimed Labs in?
Synthimed Labs's product category is Active Pharmaceutical Ingredients (API) Manufacturing. Its primary akta.pro industry code is HLAIABAG, Generic APIs & Intermediates (Active Ingredients), with a secondary code of HLAGAHAG, Impurity / Reference Standard Synthesis & Characterization. Its NAICS code is 3254 and its SIC code is 2834.